The Neuropharmacology, neuroepigenetics, neurodegeneration and aging group belonging to UBNeuro (http://www.neurociencies.ub.edu/neuropharmacology-neuroepigenetics-neurodegeneration-and-ageing/) incorporated Dr. Ana Guerrero on March 1. Dr Guerrero is a Ramón y Cajal researcher. She completed her PhD in Molecular Medicine at the University of Santiago de Compostela (USC), and held postdoctoral positions at the MRC London Institute of Medical Sciences (MRC LMS, Imperial College London, UK) and the UK Dementia Research Institute (UK DRI at University College London, The Francis Crick Institute, UK). Her postdoctoral research explored the potential of cellular senescence as a therapeutic target, leading to the identification of novel pharmacological modulators of senescence, including senolytic compounds (Guerrero et al. 2019, Nature Metabolism; Guerrero et al. 2020, Aging Cell) and drugs alleviating senescence (Guerrero et al. 2022, Nature Aging). Her current research programme explores the contribution of cellular senescence and ageing to neurodegeneration, with a particular focus on Alzheimer´s Disease.